New data from Grail’s large PATHFINDER 2 study show improved performance for the company’s Galleri multi-cancer early detection test. Investigators followed nearly 36,000 adults over age 50 and reported a sensitivity of 40.4% for cancers detected during more than one year of follow-up; roughly half of detected cancers were stage 1–2 and many were tumor types not covered by existing screening programs. The analysis also produced a positive predictive value near 62% for positive tests, a material rise from earlier studies (43–50%). Grail and study authors presented results at ESMO and to STAT, and the dataset is being used to support regulatory filings. While the numbers strengthen Galleri’s argument for broader clinical use, experts cited by STAT note unresolved questions about downstream diagnostic workflows, overdiagnosis, and the real-world logistics and economics of implementing multi-cancer blood screens at scale.